文献速递骨质疏松与代谢性骨病

口服双膦酸盐暴露与胃肠道癌症风险:韩国全国性队列研究

Exposure to oral bisphosphonates and risk of gastrointestinal cancer.
PubMed 文献 · Osteoporos Int · 2020-02-07

该研究基于韩国全国性人群队列,纳入45,397名60岁及以上女性和25,665名新诊断骨质疏松患者,评估口服双膦酸盐暴露与胃肠道癌症风险的关系。结果显示,与未使用者相比,使用者胃肠道癌(HR 1.06;95% CI 0.87-1.28)、胃癌(HR 1.11;95% CI 0.85-1.47)和结直肠癌(HR 1.04;95% CI 0.79-1.37)风险均无显著差异,且累积剂量增加与胃肠道癌症风险无关(趋势P=0.573)。

要点

  • 口服双膦酸盐使用与胃肠道癌症风险无显著关联。
  • 胃癌和结直肠癌风险在双膦酸盐使用者中亦无显著改变。
  • 累积剂量增加未显示胃肠道癌症风险升高或降低的趋势。

核心结论

  • 口服双膦酸盐使用似乎与胃肠道癌症风险升高或降低均无关。

研究设计与样本

  • 研究使用两个队列:第一个队列纳入2002-2013年韩国国民健康保险服务-健康筛查队列中45,397名60岁及以上女性,根据2002-2007年药物暴露分为双膦酸盐使用者和非使用者,从2008年1月1日索引日期随访。
  • 采用Cox比例风险回归模型评估癌症风险的风险比(HR)和95%置信区间(CI)。

主要发现

  • 与双膦酸盐非使用者相比,使用者胃肠道癌风险无显著差异(HR 1.06;95% CI 0.87-1.28)。
  • 胃癌风险无显著差异(HR 1.11;95% CI 0.85-1.47)。
  • 结直肠癌风险无显著差异(HR 1.04;95% CI 0.79-1.37)。
  • 在双膦酸盐使用者中,累积剂量增加与胃肠道癌症风险无关(趋势P=0.573)。

关键数值与推荐

  • 胃肠道癌风险HR 1.06(95% CI 0.87-1.28),对象为双膦酸盐使用者对比非使用者。
  • 胃癌风险HR 1.11(95% CI 0.85-1.47),对象为双膦酸盐使用者对比非使用者。
  • 结直肠癌风险HR 1.04(95% CI 0.79-1.37),对象为双膦酸盐使用者对比非使用者。
  • 累积剂量与胃肠道癌症风险的趋势检验P=0.573。

临床怎么用

  • 对于需要口服双膦酸盐治疗的骨质疏松患者,无需因胃肠道癌症风险担忧而改变用药决策。
  • 长期使用双膦酸盐时,仍应按常规进行健康监测,但胃肠道癌症风险未见显著增加。

局限性

  • 研究基于韩国人群,结论外推至其他亚洲人群需谨慎。
  • 观察性设计可能存在未测量的混杂因素。
  • 药物暴露基于处方记录,可能无法完全反映实际服药情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Few studies have explored the association of oral bisphosphonate exposure and gastrointestinal cancer within Asian populations. In this study, we investigated 45,397 Korean women from the nationwide population-based cohort from 2002 to 2013. Oral bisphosphonate exposure did not appear to be associated with elevated or reduced risk for gastrointestinal cancer. INTRODUCTION: While several studies suggested increased risk in upper gastrointestinal (GI) cancer or reduced risk in colorectal cancer upon bisphosphonate exposure, the association is less explored within Asian populations. We investigated the effect of oral bisphosphonate exposure on the risk of GI cancers within a nationwide population-based cohort. METHODS: This study used two separate cohorts. The first cohort included 45,397 women aged 60 years or older from the National Health Insurance Service-Health Screening Cohort during 2002-2013. Participants were classified into bisphosphonate users and non-users based on drug exposure during 2002-2007, and followed-up from the index date of January 1, 2008. The second cohort included 25,665 newly diagnosed osteoporosis patients who started taking oral bisphosphonate during 2003-2008. After 4 years of drug exposure period, patients were separated into quartiles based on cumulative oral bisphosphonate exposure. Participants were followed-up until December 31, 2013 for GI cancer, stomach cancer, and colorectal cancer. Cox proportional hazard regression models were used to assess the hazard ratios (HRs) and 95% confidence intervals (CIs) for the cancer risks. RESULTS: Compared to bisphosphonate non-users, no significant risk difference was observed among bisphosphonate users on GI (HR 1.06; 95% CI 0.87-1.28), stomach (HR 1.11; 95% CI 0.85-1.47) and colorectal cancers (HR 1.04; 95% CI 0.79-1.37). Among bisphosphonate users, increasing doses of bisphosphonate exposure was not associated with elevated or reduced risk for GI cancer (p for trend 0.573). CONCLUSION: Oral bisphosphonate use did not appear to be associated with elevated or reduced risk for GI cancers.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Choi D, Choi S, Chang J, et al. Exposure to oral bisphosphonates and risk of gastrointestinal cancer. Osteoporos Int. 2020. PMID: 32034451. doi:10.1007/s00198-020-05327-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。